Posted on August 27, 20268/27/26
The Hidden Cost of Late Evidence Planning
Posted on August 18, 20268/18/26
Evidence Hierarchies, PICO Coverage and Real-World Data: Emerging Insights from Early JCAs
Posted on August 5, 20268/5/26
Choosing the Right Indirect Treatment Comparison When Navigating Cross-Trial Heterogeneity
Posted on July 24, 20267/24/26
Comparing CDK4/6 Inhibitors in Real-World Practice: What the Evidence Reveals
Posted on May 28, 20265/28/26
Bridging Evidence Gaps in mCRPC: Highlighting the Potential of Talazoparib plus Enzalutamide
Posted on May 8, 20265/8/26
How MFN is Reshaping Global Drug Pricing – and How NAVLIN Insights Tracks It
Posted on February 11, 20262/11/26
Demonstrating the Clinical and Economic Value of Efgartigimod for AChR‑Positive gMG in Canada
Posted on December 12, 202512/12/25
Consolidating Data Strategy For Global Success
Posted on December 10, 202512/10/25